Archive

Fezolinetant cuts hot flashes for almost 6 months

Written by Bruce Sylvester | 14 May 2024

Fezolinetant 45 mg appears to be effective for up to 24 weeks in the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause in women who are considered… read more.

Developing pharmacy services for menopause management

Written by Christine Clark | 27 Apr 2024

Deborah Evans is a pharmacist and independent prescriber who specialises in women’s reproductive and sexual health, including the menopause. She owns and runs Remedi Health, an independent pharmacy… read more.

Tips for building a successful pharmacy menopause service

Written by Christine Clark | 26 Apr 2024

Working in the menopause clinic is professionally rewarding and there is a wealth of resources available for keeping up-to-date. Awareness of the latest evidence and the ability to… read more.

Choosing a transdermal oestrogen and tackling genitourinary syndrome of menopause

Written by Christine Clark | 25 Apr 2024

Transdermal oestrogen products and the management of genitourinary syndrome of menopause are two important topics in menopause management. Selecting the most appropriate treatments should take into account individual… read more.

Why you could add testosterone to menopause treatment

Written by Christine Clark | 24 Apr 2024

Testosterone is an important hormone for women and may need replacement alongside oestrogen and progesterone, says Deborah Evans, pharmacist prescriber and Clinic Director at Remedi Health. Replacing testosterone… read more.

How the benefits of hormone replacement therapy outweigh the risks

Written by Christine Clark | 23 Apr 2024

The benefits of hormone replacement therapy (HRT) using transdermal devices are considerable, including a 30% reduction in all-cause mortality, according to Deborah Evans, prescribing pharmacist and Clinic Director… read more.

How menopause affects women and why we should offer treatment

Written by Christine Clark | 22 Apr 2024

Does an early menopause transition cause women to leave the workforce sooner?

Written by Charlie King | 17 Mar 2024

Since most women will continue working for years after entering menopause, the effect of menopause symptoms on their working ability is an important issue and the focus of… read more.

Menopause and migraines: New findings point to power of prevention

Written by Charlie King | 19 Feb 2024

For middle-aged women plagued by migraines, or hot flashes and night sweats, another worry may linger in the backs of their minds: whether these experiences have set them… read more.

How ovarian tissue freezing could prevent menopause—possibly forever

Written by Charlie King | 13 Feb 2024

Most women agree that menopause has its advantages and disadvantages. Some relish the end of menstruation and concerns about unplanned pregnancies, while others dread the possibililty of hot… read more.

MHRA approves Veoza (fezolinetant) to treat vasomotor symptoms associated with menopause – Astellas

Written by Charlie King | 23 Dec 2023

Veoza (Veozah in the US), also known as fezolinetant, from Astellas, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) after receiving similar approval in… read more.

European Commission approves Veoza (fezolinetant) to treat vasomotor symptoms associated with menopause – Astellas

Written by Charlie King | 18 Dec 2023

Astellas Pharma Inc. announced the European Commission (EC) on December 7 approved Veoza (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS)… read more.

1 2 3 Next »

Archive

Subscribe for our mailing list

Follow Us